NKTR · Nektar Therapeutics

The 52-week REZOLVE-AA results represent a pivotal clinical milestone for Nektar’s rezpegaldesleukin program in alopecia areata, demonstrating not only statistically significant separation from placebo on key efficacy endpoints—SALT ≤20 (p=0.049) and SALT ≤30 (p=0.023)—but also evidence of deepening clinical response during extended twice-monthly dosing. The emergence of new SALT ≤20 responders (29–31%) between weeks 36 and 52 exclusively in the rezpegaldesleukin arms suggests a time-dependent pharmacodynamic effect consistent with Treg biology, a finding echoed by investigator commentary referencing similar patterns observed in the atopic dermatitis trial. With 94% of extension patients completing 52 weeks of treatment and zero discontinuations due to TEAEs—alongside mild, transient injection site reactions—the safety profile remains robust and differentiated from JAK inhibitors, which carry boxed warnings and require intensive lab monitoring. The global enrollment across 30 sites, with majority representation from Poland, supports feasibility of broader geographic execution in future registrational trials. Importantly, these data directly inform Phase 3 design: the extension was exploratory but strongly supports a 52-week induction duration, and the clear dose-response trend across multiple SALT thresholds reinforces confidence in selecting an optimal dose. Given the urgent unmet need in severe AA—where current JAK inhibitors face adherence challenges, high relapse rates, and safety limitations—these results materially advance rezpegaldesleukin’s positioning as a potential first-in-class biologic with a novel regulatory T-cell mechanism, elevating near-term catalyst risk and strategic partnership or development pathway options.